RxDoctor Payments Data

Basel Edris, MD

Clinical Cardiac Electrophysiology · Ashland, KYNPI 1629381116

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $30,285 of the $44,904 with a category attached, or 67.4%. 28 manufacturers reported payments, led by Abbott at 47.3% of the total. Reporting peaked in 2022 at $10,196 and has fallen 60.9% since, to $3,986 in 2025.

$44,904in general payments, 2019–2025

Across 376 payments — averaging $119.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$21K
  • Medtronic$8K
  • Biotronik Inc.$6K
  • Boston Scientific$3K
  • Medical Device Business Services, Inc.$3K
  • Biosense Webster, Inc.$658
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$30,28567%
  • Food & beverage$12,65828%
  • Education$1,9624%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,904 in reported general payments places this provider in the 75th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

See all clinical cardiac electrophysiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$184,802
Medicare patients
1,638
Services billed
3,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$25,457
XareltoRivaroxaban13$15,518
Dofetilide21$1,932
Amiodarone Hcl46$726
Flecainide Acetate11$681
Metoprolol Succinate19$179
Metoprolol Tartrate29$116
Warfarin Sodium18$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$25,45725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

Other clinical cardiac electrophysiology in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →